http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104857528-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104857528-B |
| titleOfInvention | Effects of the 5p of miR 1307 as the inhibitor of DPP IV in the diagnosis and treatment of type II diabetes |
| abstract | The invention discloses the 5p of miR 1307 or its precursor, upper adjustment and its derivative to prepare or screen the application for treating in type II diabetes medicine, and the application in terms of as the inhibitor of DPP IV；The sequence such as SEQ ID NO of the 5p of miR 1307：Shown in 1.The 5p of miR 1307 had both referred to containing SEQ ID NO：The Microrna of sequence shown in 1, also refer to synthesize in vitro there is SEQ ID NO：The upper adjustment of the Microrna of sequence shown in 1 or derivative, including its analogies, activator and protective agent etc..The 5p of miR 1307 and adjust thereon and derivative etc. can be as DPP IV specific inhibitor, for preparing or screening the active drug for the treatment of type II diabetes, diagnosis and preparation or screening medicine for type II diabetes provide new target spot, and the treatment to type II diabetes is significant. |
| priorityDate | 2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.